

## 文献検索式

### CQ01 円錐切除術で診断した CIN 3 と AIS に対して推奨される対応と治療は？

〔データベース〕 PubMed

〔検索日〕 2015 年 1 月 11 日～31 日

((("Cervical Intraepithelial Neoplasia" [MH] OR "Cervical Intraepithelial Neoplasia" [TIAB]) AND ("CIN 1,3" [TIAB] OR "CIN 2/3" [TIAB] OR "CIN 2 3" [TIAB] OR "CIN 2,3" [TIAB] OR "CIN 3" [TIAB] OR "CIN ii/iii" [TIAB] OR "CIN ii iii" [TIAB] OR "CIN iii" [TIAB] OR "CIN1,3" [TIAB] OR "CIN2/3" [TIAB] OR "CIN2 3" [TIAB] OR "CIN2,3" [TIAB] OR "CINii/iii" [TIAB] OR "CINii iii" [TIAB] OR "grade three" [TIAB] OR "CIN3" [TIAB] OR "CINiii" [TIAB] OR "grade 3" [TIAB] OR "grade iii" [TIAB] OR "grade3" [TIAB] OR "gradeiii" [TIAB] OR "grade 2, 3" [TIAB])) AND ("high grade squamous intraepithelial lesion" [TIAB] OR "high grade squamous intraepithelial lesions" [TIAB] OR "high grade squamous intraepithelial neoplasia" [TIAB] OR ("Squamous Intraepithelial Lesions" [TW] AND "High grade" [TIAB]) OR HSIL [TIAB]) AND (("preinvasive adenocarcinoma" [TIAB] OR "intraepithelial adenocarcinoma" [TIAB] OR "intraepithelial adenocarcinomas" [TIAB] OR "Adenocarcinoma in situ" [TW] OR "preinvasive lesion" [TIAB] OR "preinvasive lesions" [TIAB] OR "precancerous lesion" [TIAB] OR "precancerous lesions" [TIAB] OR AIS [TIAB]) AND (cervical [TIAB] OR cervix [TIAB])) AND (therapy [SH] OR therapy [TIAB] OR therapies [TIAB] OR therapeutic [TIAB] OR therapeutics [TIAB] OR treatment [TIAB] OR treatments [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB] OR "Conization" [MH] OR "Photochemotherapy" [MH] OR "Electrosurgery/methods" [MH] OR "photodynamic therapeutics" [TIAB] OR "photodynamic therapies" [TIAB] OR "photodynamic therapy" [TIAB] OR Photochemotherapies [TIAB] OR Photochemotherapy [TIAB] OR "electrosurgical loop excision" [TIAB] OR "loop electrosurgical excision" [TIAB] OR LEEP [TIAB] OR laser [TIAB] OR "cold knife" [TIAB])

〔データベース〕 医中誌 Web

〔検索日〕 2015 年 1 月 30 日

(((@ 子宮頸部腫瘍/TH and @ 上皮内癌/TH) or 子宮頸部上皮内腫瘍/TH or (@ 上皮内腺癌/TH and @ 子宮頸部腫瘍/TH) or (((@ 子宮頸部腫瘍/TH and @ 腺扁平上皮癌/TH) or (@ 子宮頸部腫瘍/TH and @ 扁平上皮癌/TH)) and (高度/AL or 高悪性/AL))) and ((SH= 治療, 薬物療法, 外科的療法, 放射線療法) or 円錐切除術/TH or 円錐切除/AL or ループ電極切除/AL or ループ電極手術/AL or ループ式電気/AL or コールドナイフ/AL or LEEP/AL or "loop electrosurgical excision procedure"/AL or レーザー療法/TH or レーザー療法/AL or レーザー蒸散/AL or 光化学療法/TH or 光線力学的治療/AL or 光化学療法/TH)

### CQ02 子宮温存治療後に再発した CIN 3 に対して、どのような治療が推奨されるか？

〔データベース〕 PubMed

〔検索日〕 2015 年 1 月 11 日～31 日

((("Cervical Intraepithelial Neoplasia" [MH] OR "Cervical Intraepithelial Neoplasia" [TIAB]) AND ("CIN 1,3" [TIAB] OR "CIN 2/3" [TIAB] OR "CIN 2 3" [TIAB] OR "CIN 2,3" [TIAB] OR "CIN 3" [TIAB] OR "CIN ii/iii" [TIAB] OR "CIN ii iii" [TIAB] OR "CIN iii" [TIAB] OR "CIN1,3" [TIAB] OR "CIN2/3" [TIAB] OR "CIN2 3" [TIAB] OR "CIN2,3" [TIAB] OR "CINii/iii" [TIAB] OR "CINii iii" [TIAB] OR "grade three" [TIAB] OR "CIN3" [TIAB] OR "CINiii" [TIAB] OR "grade 3" [TIAB] OR "grade iii" [TIAB] OR "grade3" [TIAB] OR "gradeiii" [TIAB] OR "grade 2, 3" [TIAB])) AND ("high grade squamous

intraepithelial lesion" [TIAB] OR "high grade squamous intraepithelial lesions" [TIAB] OR "high grade squamous intraepithelial neoplasia" [TIAB] OR ("Squamous Intraepithelial Lesions" [TW] AND "High grade" [TIAB]) OR HSIL [TIAB]) AND (("preinvasive adenocarcinoma" [TIAB] OR "intraepithelial adenocarcinoma" [TIAB] OR "intraepithelial adenocarcinomas" [TIAB] OR "Adenocarcinoma in situ" [TW] OR "pre-malignant lesion" [TIAB] OR "pre-malignant lesions" [TIAB] OR "precancerous lesion" [TIAB] OR "precancerous lesions" [TIAB] OR AIS [TIAB]) AND (cervical [TIAB] OR cervix [TIAB])) AND (therapy [SH] OR therapy [TIAB] OR therapies [TIAB] OR therapeutic [TIAB] OR therapeutics [TIAB] OR treatment [TIAB] OR treatments [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB] OR "Conization" [MH] OR "Photochemotherapy" [MH] OR "Electrosurgery/methods" [MH] OR "photodynamic therapeutics" [TIAB] OR "photodynamic therapies" [TIAB] OR "photodynamic therapy" [TIAB] OR Photochemotherapies [TIAB] OR Photochemotherapy [TIAB] OR "electrosurgical loop excision" [TIAB] OR "loop electrosurgical excision" [TIAB] OR LEEP [TIAB] OR laser [TIAB] OR "cold knife" [TIAB]) AND ("Postoperative Complications" [MH] OR "Neoplasm Recurrence, Local" [MH] OR ((Postoperative [TIAB] OR post [TIAB] OR after [TIAB]) AND (Recurrence [MH] OR Recurrence [TIAB] OR Recurrences [TIAB] OR Recrudescence [TIAB] OR Recrudescences [TIAB] OR Relapse [TIAB] OR Relapses [TIAB]))) AND (("Postoperative Complications" [MH] OR "Neoplasm Recurrence, Local" [MH] OR ((Postoperative [TIAB] OR post [TIAB] OR after [TIAB]) AND ("Recurrence" [MH] OR Recurrence [TIAB] OR Recurrences [TIAB] OR Recrudescence [TIAB] OR Recrudescences [TIAB] OR Relapse [TIAB] OR Relapses [TIAB])))

[データベース] 医中誌 Web

[検索日] 2015年1月30日

((@子宮頸部腫瘍/TH and @上皮内癌/TH) or 子宮頸部上皮内腫瘍/TH or (@上皮内腺癌/TH and @子宮頸部腫瘍/TH) or ((@子宮頸部腫瘍/TH and @腺扁平上皮癌/TH) or (@子宮頸部腫瘍/TH and @扁平上皮癌/TH)) and (高度/AL or 高悪性/AL)) and (((術後期/TH or 術後/AL) and (再発/TH or 再発/AL)) or 腫瘍再発/TH or 腫瘍再発/AL or 局所再発/AL)

### CQ03 IA1期に対して推奨される治療は？

[データベース] PubMed

[検索日] 2016年2月11日

("Adenocarcinoma" [MH] OR "Carcinoma, Squamous Cell" [MH] OR "squamous cell carcinoma" [TIAB] OR "squamous cell carcinomas" [TIAB] OR adenocarcinoma [TIAB] OR adenocarcinomas [TIAB] OR "Uterine Cervical Neoplasms" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]))) AND ("Uterine Cervical Neoplasms/therapy" [MH] OR radiotherapy [TIAB] OR radiation [TIAB] OR therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB] OR "Hysterectomy" [MH] OR hysterectomy [TIAB] OR hysterectomies [TIAB]) AND (((IA [TIAB] OR IA [TIAB] OR IA1\* [TIAB] OR IA1\* [TIAB] OR "IA 1" [TIAB] OR "IA 1" [TIAB]) AND (staging [TIAB] OR stage [TIAB] OR stages [TIAB] OR "Neoplasm Staging" [MH])) OR "early stages" [TIAB] OR "early stage" [TIAB] OR "early staging" [TIAB] OR "early invasive" [TIAB])

[データベース] 医中誌 Web

[検索日] 2015年1月31日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or (子宮頸部腫瘍/TH or 子宮頸がん/AL) or (@子宮頸部腫瘍/TH and @腺癌/TH) or 子宮頸部腺がん/AL or 子宮頸部腺癌/AL or 子宮頸部腺がん/AL or 子宮頸部腺/AL) and (治療/TH or 治療/AL or 療法/AL) and (IA期/AL or IA期/AL or 微小浸潤/AL or ステージIA/AL or ステージIA/AL or "ステージIA"/AL or "ステージIA"/AL or 癌IA/AL or 癌IA/AL or が ん IA/AL or が ん IA/AL or IA1期/AL or "IA 1期"/AL or IA1期/AL or "IA 1期"/AL or ステージIA1/AL or ステージIA1/AL or "ステージIA1"/AL or ステ

ジ IA1"/AL or (("IA 1"/AL or "IA 1"/AL) and ステージ/AL))

#### CQ04 IA 2期に対して推奨される治療は？

[データベース] PubMed

[検索日] 2016年2月11日

("Adenocarcinoma" [MH] OR "Carcinoma, Squamous Cell" [MH] OR "squamous cell carcinoma" [TIAB] OR "squamous cell carcinomas" [TIAB] OR adenocarcinoma [TIAB] OR adenocarcinomas [TIAB] OR "Uterine Cervical Neoplasms" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]))) AND ("Uterine Cervical Neoplasms/therapy" [MH] OR radiotherapy [TIAB] OR radiation [TIAB] OR therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB] OR "Hysterectomy" [MH] OR hysterectomy [TIAB] OR hysterectomies [TIAB]) AND ((IA2\* [TIAB] OR IA2\* [TIAB] OR "IA 2" [TIAB] OR "IA 2" [TIAB]) AND (staging [TIAB] OR stage [TIAB] OR stages [TIAB] OR "Neoplasm Staging" [MH]))

[データベース] 医中誌 Web

[検索日] 2015年1月31日～2月5日

((子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or (子宮頸部腫瘍/TH or 子宮頸がん/AL)) or ((@ 子宮頸部腫瘍/TH and @ 腺癌/TH) or 子宮頸部腺がん/AL or 子宮頸部腺癌/AL or 子宮頸部腺がん/AL or 子宮頸部腺/AL)) and (治療/TH or 治療/AL or 療法/AL) and (IA 期/AL or IA 期/AL or 微小浸潤/AL or ステージ IA/AL or ステージ IA/AL or "ステージ IA"/AL or "ステージ IA"/AL or 癌 IA/AL or 癌 IA/AL or が ん IA/AL or が ん IA/AL or IA2期/AL or "IA 2期"/AL or IA2期/AL or "IA 2期"/AL or ステージ IA2/AL or ステージ IA2/AL or "ステージ IA2"/AL or "ステージ IA2"/AL or ("IA 2"/AL or "IA 2"/AL) and ステージ/AL))

#### CQ05 単純子宮全摘出術後に IB 期またはそれ以上と診断された場合、推奨される治療は？

[データベース] PubMed

[検索日] 2015年1月9日～28日

("Adenocarcinoma" [MH] OR "Carcinoma, Squamous Cell" [MH] OR "squamous cell carcinoma" [TIAB] OR "squamous cell carcinomas" [TIAB] OR adenocarcinoma [TIAB] OR adenocarcinomas [TIAB] OR ("Uterine Cervical Neoplasms" [MH] OR ((cervical cancer" [TIAB] OR "cervical cancers" [TIAB] OR "cervix cancer" [TIAB] OR "cervix cancers" [TIAB] OR "cervical cancer" [TIAB] OR "cervical cancers" [TIAB] OR "cervix neoplasm" [TIAB] OR "cervix neoplasms" [TIAB] OR "cervical neoplasm" [TIAB] OR "cervical neoplasms" [TIAB] OR "cervix carcinoma" [TIAB] OR "cervix carcinomas" [TIAB] OR "cervical carcinoma" [TIAB] OR "cervical carcinomas" [TIAB]) NOT medline [SB])) AND ("simple" [TIAB] OR "total" [TIAB] OR "extrafascial" [TIAB]) AND (hysterectomy [TIAB] OR hysterectomies [TIAB] OR "Hysterectomy" [MH])) AND (Postoperative [TIAB] OR posthysterectomy [TIAB] OR "Postoperative Complications" [MH] OR "Postoperative Care" [MH] OR "Incidental Findings" [MH] OR "Neoplasm Recurrence, Local" [MH] OR "found in" [TIAB] OR "following" [TIAB] OR post [TIAB] OR after [TIAB])

[データベース] 医中誌 Web

[検索日] 2015年1月11日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL or (子宮摘出術/TH and 単純/AL) or 単純子宮全摘出/AL or 単純子宮摘出/AL) and (術後期/TH or 術後/AL or 腫瘍進行度/TH or ステージ/AL))

**CQ06** I B1・II A 1 期扁平上皮癌に対して推奨される治療は？

〔データベース〕 PubMed

〔検索日〕 2016年2月3日

("Uterine Cervical Neoplasms/therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]))) AND (radiotherapy [TIAB] OR radiation [TIAB] OR therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB]) AND ("Carcinoma, Squamous Cell" [MH] OR "Neoplasms, Squamous Cell" [MH] OR ((Squamous Cell\* [TIAB]) AND (Carcinoma [TIAB] OR Neoplasm\* [TIAB]))) AND ((IB1\* [TIAB] OR IIA1\* [TIAB] OR IB1\* [TIAB] OR 2A1\* [TIAB]) AND (stage\* [TIAB] OR "Neoplasm Staging" [MH])) OR ((IB2\* [TIAB] OR IIA2\* [TIAB] OR IB2\* [TIAB] OR 2A2\* [TIAB]) AND (stage\* [TIAB] OR "Neoplasm Staging" [MH])) OR ((IIB\* [TIAB] OR 2B [TIAB] OR 2B1\* [TIAB] OR 2B2\* [TIAB]) AND (stage\* [TIAB] OR "Neoplasm Staging" [MH]))

〔データベース〕 医中誌 Web

〔検索日〕 2016年2月3日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (扁平上皮癌/TH or 扁平上皮癌/AL or 有棘細胞癌/AL or 有棘細胞がん/AL or 扁平細胞癌/AL or 扁平細胞がん/AL) and ((SH= 治療の利用, 治療, 薬物療法, 外科的療法, 食事療法, 放射線療法) or 治療/TH or 治療/AL or 療法/AL) and (I期/AL OR II期/AL OR 1期/AL OR 2期/AL OR ステージ1/AL OR ステージ2/AL OR ステージI/AL OR ステージII/AL or IB/AL OR IB/AL OR IIA/AL OR 2A/AL or IB1/AL OR IB1/AL OR IIA1/AL OR 2A1/AL or IB2/AL OR IB2/AL OR IIA2/AL OR 2A2/AL or II期/AL OR 2期/AL or IIB/AL OR 2B/AL or 腫瘍進行度/TH)

**CQ07** I B2・II A 2 期扁平上皮癌に対して推奨される治療は？

〔データベース〕 PubMed

〔検索日〕 2016年2月3日

("Uterine Cervical Neoplasms/therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]))) AND (radiotherapy [TIAB] OR radiation [TIAB] OR therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB]) AND ("Carcinoma, Squamous Cell" [MH] OR "Neoplasms, Squamous Cell" [MH] OR ((Squamous Cell\* [TIAB]) AND (Carcinoma [TIAB] OR Neoplasm\* [TIAB]))) AND (IB1\* [TIAB] OR IIA1\* [TIAB] OR IB1\* [TIAB] OR 2A1\* [TIAB] OR IB2\* [TIAB] OR IIA2\* [TIAB] OR IB2\* [TIAB] OR 2A2\* [TIAB] OR IIB\* [TIAB] OR 2B [TIAB] OR 2B1\* [TIAB] OR 2B2\* [TIAB]) AND (stage\* [TIAB] OR "Neoplasm Staging" [MH])

〔データベース〕 医中誌 Web

〔検索日〕 2016年2月3日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (扁平上皮癌/TH or 扁平上皮癌/AL or 有棘細胞癌/AL or 有棘細胞がん/AL or 扁平細胞癌/AL or 扁平細胞がん/AL) and ((SH= 治療の利用, 治療, 薬物療法, 外科的療法, 食事療法, 放射線療法) or 治療/TH or 治療/AL or 療法/AL) and (I期/AL OR II期/AL OR 1期/AL OR 2期/AL OR ステージ1/AL OR ステージ2/AL OR ステージI/AL OR ステージII/AL or IB/AL OR IB/AL OR IIA/AL OR 2A/AL or IB1/AL OR IB1/AL OR IIA1/AL OR 2A1/AL or IB2/AL OR IB2/AL OR IIA2/AL OR 2A2/AL or II期/AL OR 2期/AL or IIB/AL OR 2B/AL or 腫瘍進行度/TH)

**CQ08** II B 期扁平上皮癌に対して推奨される治療は？

〔データベース〕 PubMed

〔検索日〕 2016年2月2日

("Uterine Cervical Neoplasms/therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]))) AND (radiotherapy [TIAB] OR radiation [TIAB] OR therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB]) AND ("Carcinoma, Squamous Cell" [MH] OR "Neoplasms, Squamous Cell" [MH] OR ((Squamous Cell\* [TIAB]) AND (Carcinoma [TIAB] OR Neoplasm\* [TIAB]))) AND (IB1\* [TIAB] OR IIA1\* [TIAB] OR IB1\* [TIAB] OR 2A1\* [TIAB] OR IB2\* [TIAB] OR IIA2\* [TIAB] OR IB2\* [TIAB] OR 2A2\* [TIAB] OR IIB\* [TIAB] OR 2B [TIAB] OR 2B1\* [TIAB] OR 2B2\* [TIAB]) AND (stage\* [TIAB] OR "Neoplasm Staging" [MH])

〔データベース〕 医中誌 Web

〔検索日〕 2016年2月3日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (扁平上皮癌/TH or 扁平上皮癌/AL or 有棘細胞癌/AL or 有棘細胞がん/AL or 扁平細胞癌/AL or 扁平細胞がん/AL) and ((SH= 治療的利用, 治療, 薬物療法, 外科的療法, 食事療法, 放射線療法) or 治療/TH or 治療/AL or 療法/AL) and (I期/AL OR II期/AL OR 1期/AL OR 2期/AL OR ステージ1/AL OR ステージ2/AL OR ステージI/AL OR ステージII/AL or IB/AL OR IB/AL OR IIA/AL OR 2A/AL or IB1/AL OR IB1/AL OR IIA1/AL OR 2A1/AL or IB2/AL OR IB2/AL OR IIA2/AL OR 2A2/AL or II期/AL OR 2期/AL or IIB/AL OR 2B/AL or 腫瘍進行度/TH)

### CQ09 IB・II期扁平上皮癌に対して術前化学療法(NAC)は推奨されるか？

〔データベース〕 PubMed

〔検索日〕 2016年3月2日

("Uterine Cervical Neoplasms/therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]))) AND ("Carcinoma, Squamous Cell" [MH] OR "Neoplasms, Squamous Cell" [MH] OR ((Squamous Cell\* [TIAB]) AND (Carcinoma [TIAB] OR Neoplasm\* [TIAB]))) AND (Neoadjuvant Therapy [MH] OR (neoadjuvant [TIAB] AND (radiotherapy [TIAB] OR radiation [TIAB] OR therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB]))) AND ((IIB\* [TIAB] OR 2B [TIAB] OR 2B1\* [TIAB] OR 2B2\* [TIAB]) AND (stage\* [TIAB] OR "Neoplasm Staging" [MH]))

〔データベース〕 医中誌 Web

〔検索日〕 2016年3月4日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (扁平上皮癌/TH or 扁平上皮癌/AL or 有棘細胞癌/AL or 有棘細胞がん/AL or 扁平細胞癌/AL or 扁平細胞がん/AL) and (ネオアジュバント療法/TH or ネオアジュバント療法/AL or (術前/AL and (放射線化学療法/TH or 放射線化学療法/AL)) or (術前/AL and (科学/AL or 放射線/AL or 照射/AL or 化療/AL or (SH= 治療的利用, 治療, 薬物療法, 放射線療法)))) and (I期/AL OR II期/AL OR 1期/AL OR 2期/AL OR ステージ1/AL OR ステージ2/AL OR ステージI/AL OR ステージII/AL or IB/AL OR IB/AL or 腫瘍進行度/TH)

### CQ10 IB・II期に対して腹腔鏡下手術, ロボット支援下手術は推奨されるか？

〔データベース〕 PubMed

〔検索日〕 2016年3月4日

("Uterine Cervical Neoplasms/surgery" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]))) AND (("Laparoscopy/surgery" [MH] or (laparoscop\* [TIAB] OR peritoneoscop\* [TIAB] OR celioscop\* [TIAB]) AND (surger\* [TIAB] OR

surgical [TIAB])) OR "Robotic Surgical Procedures" [MH] OR "Robotics" [MH] OR robotic\* [TIAB])

[データベース] 医中誌 Web

[検索日] 2016年3月4日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (腹腔鏡法/TH or 腹腔鏡法/AL or 腹腔鏡下/AL or 体腔鏡手術/AL or 腹腔鏡手術/AL) and (ロボット手術/TH or コンピュータ思念手術/TH or ロボット工学/TH or ロボット手術/AL or ロボット支援/AL or 手術支援ロボット/AL or ロボット/AL)

## CQ11 子宮温存術式の適応は？

[データベース] PubMed

[検索日] 2016年3月7日

("Uterine Cervical Neoplasms/surgery" [MH] OR (((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB] OR adenocarcinoma\* [TIAB] OR adeno carcinoma\* [TIAB])) AND (surgical treatment [TIAB] or operation [TIAB] or operate [TIAB] or operating [TIAB] or operative [TIAB] or postoperative [TIAB] or surgery [TIAB]))) AND (Trachelectomy [MH] or trachelectom\* [TIAB] or cervicectom\* [TIAB]) AND ("Fertility Preservation" [MH] or (Fertility [TIAB] and preserv\* [TIAB]) OR Pregnancy [MH] or Pregnanc\* [TIAB] or Gestation [TIAB]))

[データベース] 医中誌 Web

[検索日] 2016年3月7日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (子宮頸部切除術/TH or 子宮頸部切除/AL or 子宮頸部摘出/AL or 子宮頸部切断/AL) and (妊孕性温存/TH or ((妊孕性/AL or 妊孕/AL) and (温存/AL or 保持/AL or 保存/AL)))

## CQ12 センチネルリンパ節生検によるリンパ節郭清の省略は推奨されるか？

[データベース] PubMed

[検索日] 2016年3月7日

("Uterine Cervical Neoplasms/diagnosis" [MAJR] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB] OR adenocarcinoma\* [TIAB] OR adeno carcinoma\* [TIAB]) AND (diagnos\* [TIAB] OR patholog\* [TIAB]) NOT medline [SB])) OR ((("Uterine Cervical Neoplasms/surgery" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB] OR adenocarcinoma\* [TIAB] OR adeno carcinoma\* [TIAB]) AND (surgery [TIAB] OR surgical [TIAB] OR operation\* [TIAB]) NOT medline [SB])) AND ("Lymph Node Excision" [MH] OR lymhadenectom\* [TIAB] OR (lymph [TIAB] AND node [TIAB] AND (dissection\* [TIAB] OR excision\* [TIAB]))) AND ("Sentinel Lymph Node Biopsy" [MH] OR (biopsy [TIAB] AND sentinel [TIAB] AND (node [TIAB] OR nodes [TIAB])))

[データベース] 医中誌 Web

[検索日] 2016年3月7日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (センチネルリンパ節/AL OR センチネルリンパ節/TH OR センチネルリンパ節生検/AL OR センチネルリンパ節生検/TH OR ((センチネルリンパ節/AL OR 前哨リンパ節/AL) AND (検査/AL OR 生検/AL OR 診断/AL)) and (リンパ節郭清/TH OR (リンパ節/AL AND (郭清/AL OR 廓清/AL OR 摘出/AL OR 切除/AL)) or (SH= 診断の利用, 診断, 画像診断, X線診断, 放射性核種診断, 超音波診断) or 診断/TH OR 診断/AL)

**CQ13** 広汎子宮全摘出術の場合に卵巣温存は推奨されるか？

〔データベース〕 PubMed

〔検索日〕 2016年2月29日

("Uterine Cervical Neoplasms/surgery" [MH] OR (((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB] OR adenocarcinoma\* [TIAB] OR adeno carcinoma\* [TIAB]))) AND ("Hysterectomies" [MH] OR hysterectomy [TIAB] OR hysterectomies [TIAB] OR surgical treatment [TIAB] OR operation [TIAB] OR operate [TIAB] OR operating [TIAB] OR operative [TIAB] OR postoperative [TIAB] OR surgery [TIAB]))) AND (((("Ovary" [MH] OR ovary [TIAB] OR ovarian [TIAB] OR ovaries [TIAB]) and (preserv\* [TIAB] OR conserv\* [TIAB] OR transposition\* [TIAB])) OR ("Ovariectomy" [MH] OR ovariectomies [TIAB] OR oophorectomy [TIAB] OR oophorectomies [TIAB]) and (preserv\* [TIAB] OR conserv\* [TIAB] OR transposition\* [TIAB])))

〔データベース〕 医中誌 Web

〔検索日〕 2016年2月29日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (子宮摘出術/TH or 子宮摘出/AL or 子宮全摘/AL or 子宮全摘手術/AL or 子宮全摘出術/AL) and (臓器温存療法/TH or 臓器温存療法/AL or 臓器温存術/AL or 臓器温存治療/AL or 機能温存療法/AL or 機能温存治療/AL or 保存手術/AL or 保存的治療/AL or 保存療法/AL or 温存療法/AL or 卵巣温存療法/AL or 卵巣温存/AL) and (卵巣/TH or 卵巣/AL)

**CQ14** IB・II期に対する傍大動脈リンパ節郭清・生検の意義は？

〔データベース〕 PubMed

〔検索日〕 2016年3月7日

("Uterine Cervical Neoplasms/therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]) AND (therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB] OR surgery [TIAB] OR surgical [TIAB] OR operati\* [TIAB] OR hysterectom\* [TIAB]) NOT medline [SB])) AND (((para-aortic [TIAB] OR paraaortic [TIAB]) AND ("Lymphatic Irradiation" [MH] OR "Lymphatic Metastasis" [MH] OR "Lymphatic Diseases" [MH] OR "Lymph Nodes" [MH] OR lymph node\* [TIAB])) OR (para aortic node\* [TIAB] OR paraaortic node\* [TIAB])) AND ("Lymph Node Excision" [MH] OR lymph node excision\* [TIAB] OR lymphadenectomy [TIAB] OR lymph node dissection\* [TIAB])

〔データベース〕 医中誌 Web

〔検索日〕 2016年3月7日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and ((大動脈/TH or 傍大動脈/AL) and ((SH= 治療的利用, 治療, 薬物療法, 外科的療法, 移植, 食事療法, 精神療法, 放射線療法) or 治療/TH or 治療/AL or 療法/AL) or センチネルリンパ節生検/TH or リンパ節生検/AL)

**CQ15** IB・II期腺癌に対して推奨される治療は？

〔データベース〕 PubMed

〔検索日〕 2016年3月7日

("Uterine Cervical Neoplasms/therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]))) AND ("Adenocarcinoma" [MH] OR "Carcinoma, Endometrioid" [MH] OR adenocarcinoma [TIAB] OR (endometrioid [TIAB] AND (carcinoma [TIAB] OR neoplasm\* [TIAB]))) AND ("Radiotherapy" [MH] OR radiotherapy [TIAB])

OR irradiation [TIAB] OR "Radiation/therapeutic use" [MH] OR (radiation [TIAB] AND therap\* [TIAB])) AND ((IB\* [TI] OR stage IB\* [TIAB] OR IIA\* [TIAB] OR IB\* [TI] OR stage IB\* [TIAB] OR 2A\* [TI] OR stage 2A\* [TIAB]) AND (stage\* [TIAB] OR "Neoplasm Staging" [MH])) OR (("Adenocarcinoma" [MH] OR "Carcinoma, Endometrioid" [MH] OR adenocarcinoma [TIAB] OR (endometrioid [TIAB] AND (carcinoma [TIAB] OR neoplasm\* [TIAB]))) AND ("Uterine Cervical Neoplasms/therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]) AND (therap\* [TIAB] OR treatment\* [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB] OR radiation\* [TIAB] OR irradiation\* [TIAB] OR radiotherap\* [TIAB] OR CCRT [TIAB] OR chemoradiotherap\* [TIAB] OR chemoradiation\* [TIAB] OR radiochemotherap\* [TIAB] OR surgery [TIAB] OR surgical [TIAB] OR operati\* [TIAB]))) ("Uterine Cervical Neoplasms/therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]) AND (therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB] OR radiotherapy [TIAB] OR radiation [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB] OR surgery [TIAB] OR surgical [TIAB] OR operati\* [TIAB] OR hysterectom\* [TIAB]) NOT medline [SB])) AND ("Carcinoma, Neuroendocrine" [MH] OR "Neuroendocrine Tumors" [MH] OR neuroendocrine [TIAB] OR "Carcinoma, Small Cell" [MH] OR small cell carcinoma\* [TIAB]) OR (gastric type [TIAB] and ("Adenocarcinoma" [MH] OR "Carcinoma, Endometrioid" [MH] OR adenocarcinoma [TIAB] OR (endometrioid [TIAB] AND (carcinoma [TIAB] OR neoplasm\* [TIAB]))) OR ((Adenocarcinoma [MH] and malignum [TIAB]) AND adenoma malignum [TIAB] or minimal deviation adenocarcinoma [TIAB] or Minimal deviation variant [TIAB])

[データベース] 医中誌 Web

[検索日] 2016年3月7日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (腺癌/TH or 腺癌/AL or 管状癌/AL or 顆粒細胞癌/AL) and (放射線療法/TH or 放射線療法/AL or 放射線治療/AL or 科学/AL or 放射線/AL or 照射/AL or 化療/AL or 治療/AL or 療法/AL or (SH=治療の利用, 治療, 薬物療法, 放射線療法) and (I期/AL OR II期/AL OR 1期/AL OR 2期/AL OR ステージI/AL OR ステージ2/AL OR ステージI/AL OR ステージII/AL or IB/AL OR IB/AL OR IIA/AL OR 2A/AL or 腫瘍進行度/TH)

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (((神経内分泌腫瘍/TH or 神経内分泌癌/TH or 神経内分泌/AL) and ((SH=治療の利用, 治療, 薬物療法, 外科的療法, 移植, 食事療法, 精神療法, 放射線療法) or 治療/TH or 治療/AL or 療法/AL)) or 小細胞癌/TH or 小細胞/AL or (胃型/AL and (腺癌/TH or 腺癌/AL or 管状癌/AL or 顆粒細胞癌/AL)) or 悪性腺腫/AL or 最小偏倚型粘液性腺癌/AL)

## CQ16 推奨される術後補助療法は？

[データベース] PubMed

[検索日] 2016年2月2日

("Uterine Cervical Neoplasms/surgery" [MH] OR ((cervical [TI] OR cervix [TI]) AND (cancer [TI] OR neoplasm\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]) NOT medline [SB])) AND (chemotherap\* [TI] OR "Drug Therapy" [MH] OR "Uterine Cervical Neoplasms/drug therapy" [MH] OR radiation\* [TI] OR "Radiotherapy" [MH] OR "Uterine Cervical Neoplasms/radiotherapy" [MH] OR combined modality therap\* [TI] OR "Combined Modality Therapy" [MH]) AND (postoperative\* [TI] OR (after [TI] AND (radical [TI] OR surgery [TI])))

[データベース] 医中誌 Web

[検索日] 2016年2月2日

(子宮頸部腫瘍/TH OR 子宮頸部腫瘍/AL OR 子宮頸癌/AL OR 子宮頸癌/AL OR 子宮頸がん/AL OR 子宮頸がん/AL) AND (化学療法/AL OR 薬物療法/AL OR 治療薬/AL or 放射線療法/TH OR 放射線療法/AL



OR 放射線治療/AL OR 全骨盤照射/AL or 集学的治療/TH OR 補助療法/AL OR 集学的治療/AL OR 併用療法/AL) AND 術後/AL

### CQ17 術後補助放射線治療を施行する場合、推奨される照射方法は？

[データベース] PubMed

[検索日] 2016年2月25日, 4月21日

((("Uterine Cervical Neoplasms/surgery" [MH] OR ((cervical [TI] OR cervix [TI]) AND (cancer [TI] OR neoplasm\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]) NOT medline [SB]))) AND (radiation\* [TI] OR irradiation\* [TI] OR radiotherap\* [TI] OR "Radiotherapy" [MH] OR "Uterine Cervical Neoplasms/radiotherapy" [MH] OR adjuvant therap\* [TIAB] OR adjuvant radiation therap\* [TIAB] OR adjuvant radiotherap\* [TIAB] OR "Radiotherapy, Adjuvant" [MH] OR whole pelvic radiotherap\* [TIAB] OR intensity-modulated radiation therap\* [TIAB] OR "Radiotherapy, Intensity-Modulated" [MH]) AND (postoperative\* [TIAB] OR post-operative\* [TIAB] OR "after surgery" [TIAB] OR (after [TI] AND radical [TI]))) OR (((("Uterine Cervical Neoplasms/surgery" [MH] OR "Endometrial Neoplasms/surgery" [MH] OR ((cervical [TI] OR cervix [TI] OR endometrial [TI]) AND (cancer [TI] OR neoplasm\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]) NOT medline [SB]))) AND (radiation\* [TI] OR irradiation\* [TI] OR radiotherap\* [TI] OR "Radiotherapy" [MH] OR "Uterine Cervical Neoplasms/radiotherapy" [MH] OR adjuvant therap\* [TIAB] OR adjuvant radiation therap\* [TIAB] OR adjuvant radiotherap\* [TIAB] OR "Radiotherapy, Adjuvant" [MH] OR whole pelvic radiotherap\* [TIAB] OR intensity-modulated radiation therap\* [TIAB] OR "Radiotherapy, Intensity-Modulated" [MH])) OR "Uterine Cervical Neoplasms/radiotherapy" [MAJR]) AND ("Postoperative Care" [MH] OR postoperative\* [TIAB] OR post-operative\* [TIAB] OR "after surgery" [TIAB] OR posthysterectomy [TI] OR (after [TI] AND radical [TI]) OR (after [TI] AND hysterectomy [TI])))

[データベース] 医中誌 Web

[検索日] 2016年2月25日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (術後補助療法/AL or (アジュバント放射線/AL not ネオアジュバント放射線/AL) or アジュバント放射線療法/TH or アジュバント放射線化学療法/TH or 術後放射線治療/AL or 術後放射線療法/AL or ((アジュバント放射線療法/AL or アジュバント放射線化学療法/AL) not (ネオアジュバント放射線療法/AL or ネオアジュバント放射線化学療法/AL))) or 強度変調放射線治療/TH or 全骨盤照射/AL or 強度変調放射線治療/AL) and 術後/AL

### CQ18 傍大動脈リンパ節領域への予防照射の適応は？

[データベース] PubMed

[検索日] 2016年1月6日

("Uterine Cervical Neoplasms/therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]) AND (prevent\* [TIAB] OR radiotherapy [TIAB] OR radiation [TIAB] OR therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB]) NOT medline [SB])) AND (((para-aortic [TIAB] OR paraaortic [TIAB]) AND ("Lymphatic Irradiation" [MH] OR "Lymphatic Metastasis" [MH] OR "Lymphatic Diseases" [MH] OR "Lymph Nodes" [MH] OR lymph node\* [TIAB])) OR para aortic node\* [TIAB] OR paraaortic node\* [TIAB])

[データベース] 医中誌 Web

[検索日] 2015年12月28日

(子宮頸部腫瘍/TH OR 子宮頸部腫瘍/AL OR 子宮頸癌/AL OR 子宮頸癌/AL OR 子宮頸がん/AL OR 子宮

頸がん/AL) and (大動脈/TH OR 傍大動脈/AL) and (リンパ行性転移/TH OR リンパ節郭清/TH OR リンパ系疾患/TH OR リンパ節/TH OR リンパ節/AL) AND ((SH= 放射線療法) or 放射線療法/TH or 放射線/AL OR 照射/AL)

### CQ19 Ⅲ・ⅣA 期に対する初回放射線治療では、放射線治療単独と同時化学放射線療法 (CCRT)

のいずれが推奨されるか？

[データベース] PubMed

[検索日] 2016年2月25日, 5月14日

((("Uterine Cervical Neoplasms/radiotherapy" [MH] OR ("Uterine Cervical Neoplasms/therapy" [MH] AND "Radiotherapy" [MH]) OR ((cervical [TI] OR cervix [TI]) AND (cancer [TI] OR neoplasm\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]) AND (radiation\* [TI] OR irradiation\* [TI] OR radiotherap\* [TI]))) AND ("Uterine Cervical Neoplasms/drug therapy" [MH] OR ("Uterine Cervical Neoplasms/therapy" [MH] AND "Drug Therapy" [MH]) OR ((cervical [TI] OR cervix [TI]) AND (cancer [TI] OR neoplasm\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]) AND (drug therap\* [TI] OR chemotherap\* [TI] OR pharmacotherap\* [TI]))) OR ("Uterine Cervical Neoplasms/therapy" [MH] AND "Combined Modality Therapy" [MH]) OR ((cervical [TI] OR cervix [TI]) AND (cancer [TI] OR neoplasm\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]) AND (CCRT [TI] OR combined modality therap\* [TI] OR chemoradiotherap\* [TI] OR chemo radiotherap\* [TI] OR chemoradiation\* [TI] OR radiochemotherap\* [TI])) AND (locally advanced stage\* [TIAB] OR stage III\* [TIAB] OR stage IV\* [TIAB] OR stage I-III\* [TIAB] OR stage I-IV\* [TIAB] OR stage II/III\* [TIAB] OR stage II-III\* [TIAB] OR stage II-IV\* [TIAB] OR stage IIA-III\* [TIAB] OR stage IIB-III\* [TIAB] OR stage IIA-IV\* [TIAB] OR stage IIB-IV\* [TIAB] OR stage 3\* [TIAB] OR stage 4\* [TIAB] OR stage 1-3\* [TIAB] OR stage 1-4\* [TIAB] OR stage 2-3\* [TIAB] OR stage 2-4\* [TIAB] OR stage 2a-3\* [TIAB] OR stage 2a-4\* [TIAB] OR ("Neoplasm Staging" [MH] AND (III [TI] OR 3 [TI] OR IVA [TI] OR 4a [TI])))

[データベース] 医中誌 Web

[検索日] 2016年2月25日

((子宮頸部腫瘍/TH and (SH= 放射線療法)) OR (子宮頸部腫瘍/TH and 放射線療法/TH) OR ((子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (放射線療法/AL or 放射線治療/AL or 化学放射線療法/AL))) and ((子宮頸部腫瘍/TH and (SH= 薬物療法)) or (子宮頸部腫瘍/TH and 薬物療法/TH) or ((子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (薬物療法/AL or 薬物治療/AL or 放射線化学療法/AL))) or (子宮頸部腫瘍/TH and 集学的治療/TH) or ((子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (集学的治療/AL or 集学的療法/AL)) and ((IIIA/AL or IIIB/AL or III期/AL or IVA/AL or 3期/AL or 3a/AL or 3b/AL or 4a/AL or "stage III"/AL or "stage 3"/AL or "stage IVA"/AL or "stage 4a"/AL or "stage 1-3"/AL or "stage 2-3"/AL or ステージ III/AL or ステージ 3/AL or ステージ IVA/AL or ステージ 4a/AL or ステージ 1-3/AL or ステージ 2-3/AL) or (腫瘍進行度/TH and (III/TI or 3a/TI or 3b/TI or 3-4/TI or IVA/TI or 4a/TI)) or 局所進行/AL)

### CQ20 Ⅲ・ⅣA 期に対して同時化学放射線療法 (CCRT) を施行する場合、推奨される薬剤は？

[データベース] PubMed

[検索日] 2016年3月9日

((("Uterine Cervical Neoplasms/drug therapy" [MH] OR ("Uterine Cervical Neoplasms/therapy" [MH] AND "Drug Therapy" [MH]) OR ((cervical [TI] OR cervix [TI]) AND (cancer [TI] OR neoplasm\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]) AND (drug therap\* [TI] OR chemotherap\* [TI] OR pharmacotherap\* [TI]))) AND ("Uterine Cervical Neoplasms/radiotherapy" [MH] OR ("Uterine Cervical Neoplasms/therapy" [MH] AND "Radiotherapy" [MH]) OR ((cervical [TI] OR cervix [TI])

AND (cancer [TI] OR neoplasm\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]) AND (radiation\* [TI] OR irradiation\* [TI] OR radiotherap\* [TI])) OR ("Uterine Cervical Neoplasms/therapy" [MH] AND "Combined Modality Therapy" [MH]) OR ((cervical [TI] OR cervix [TI]) AND (cancer [TI] OR neoplasm\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]) AND (CCRT [TI] OR combined modality therap\* [TI] OR chemoradiotherap\* [TI] OR chemo radiotherap\* [TI] OR chemoradiation\* [TI] OR radiochemotherap\* [TI])) AND (("locally advanced" [TIAB] AND (stage [TIAB] OR stages [TIAB])) OR (stage III\* [TIAB] OR stage IV\* [TIAB] OR stage I-III\* [TIAB] OR stage I-IV\* [TIAB] OR stage II/III\* [TIAB] OR stage II-III\* [TIAB] OR stage II-IV\* [TIAB] OR stage IIA-III\* [TIAB] OR stage IIB-III\* [TIAB] OR stage IIA-IV\* [TIAB] OR stage IIB-IV\* [TIAB] OR stage 3\* [TIAB] OR stage 4\* [TIAB] OR stage 1-3\* [TIAB] OR stage 1-4\* [TIAB] OR stage 2-3\* [TIAB] OR stage 2-4\* [TIAB] OR stage 2a-3\* [TIAB] OR stage 2a-4\* [TIAB] OR ("Neoplasm Staging" [MH] AND (III [TI] OR 3 [TI] OR IVA [TI] OR 4a [TI]))))

[データベース] 医中誌 Web

[検索日] 2016年3月9日

((子宮頸部腫瘍/TH and (SH=薬物療法)) or (子宮頸部腫瘍/TH and 薬物療法/TH) or ((子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (薬物療法/AL or 薬物治療/AL or 放射線化学療法/AL))) and ((子宮頸部腫瘍/TH and (SH=放射線療法)) or (子宮頸部腫瘍/TH and 放射線療法/TH) or ((子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (放射線療法/AL or 放射線治療/AL or 化学放射線療法/AL))) or (子宮頸部腫瘍/TH and 集学的治療/TH) or ((子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (集学的治療/AL or 集学的療法/AL)) and (IIIA/AL or IIIB/AL or III期/AL or IVA/AL or 3期/AL or 3a/AL or 3b/AL or 4a/AL or "stage III"/AL or "stage 3"/AL or "stage IVA"/AL or "stage 4a"/AL or "stage 1-3"/AL or "stage 2-3"/AL or ステージ III/AL or ステージ 3/AL or ステージ IVA/AL or ステージ 4a/AL or ステージ 1-3/AL or ステージ 2-3/AL or (腫瘍進行度/TH and (III/TI or 3a/TI or 3b/TI or 3-4/TI or IVA/TI or 4a/TI)) or 局所進行/AL)

### CQ21 Ⅲ・ⅣA期に対して主治療前に施行する化学療法は推奨されるか？

[データベース] PubMed

[検索日] 2016年2月26日

("Uterine Cervical Neoplasms/drug therapy" [MH] AND "Uterine Cervical Neoplasms/radiotherapy" [MH]) OR ("Uterine Cervical Neoplasms/drug therapy" [MH] AND "Radiotherapy" [MH]) OR ("Uterine Cervical Neoplasms/therapy" [MH] AND "Chemoradiotherapy" [MH]) OR ("Uterine Cervical Neoplasms/therapy" [MH] AND "Radiotherapy, Adjuvant" [MH]) OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR adenocarcinoma\* [TIAB] OR adeno carcinoma\* [TIAB] OR adeno carcinoma\* [TIAB]) AND ((drug therap\* [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB]) AND (radiation\* [TIAB] OR irradiation\* [TIAB] OR radiotherap\* [TIAB])) OR CCRT [TIAB] OR combined modality therap\* [TIAB] OR chemoradiotherap\* [TIAB] OR chemo radiotherap\* [TIAB] OR chemoradiation\* [TIAB] OR radiochemotherap\* [TIAB])) OR ("Uterine Cervical Neoplasms/drug therapy" [MH] AND "Uterine Cervical Neoplasms/surgery" [MH]) OR ("Uterine Cervical Neoplasms/drug therapy" [MH] AND "Surgical Procedures, Operative" [MH]) OR ("Uterine Cervical Neoplasms/therapy" [MH] AND "Chemotherapy, Adjuvant" [MH]) OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR adenocarcinoma\* [TIAB] OR adeno carcinoma\* [TIAB]) AND (drug therap\* [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB] OR CCRT [TIAB] OR combined modality therap\* [TIAB] OR chemoradiotherap\* [TIAB] OR chemo radiotherap\* [TIAB] OR chemoradiation\* [TIAB] OR radiochemotherap\* [TIAB]) AND (surgical [TIAB] OR surgery [TIAB] OR operati\* [TIAB] OR postoperat\* [TIAB])) OR (("Uterine Cervical Neoplasms/drug therapy" [MH] AND "Adenocarcinoma/therapy" [MH]) OR ("Uterine Cervical Neoplasms/therapy" [MH] AND "Adenocarcinoma/drug therapy" [MH])) OR ("Uterine Cervical Neoplasms/therapy" [MH] AND

"Combined Modality Therapy" [MH]) OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR adenocarcinoma\* [TIAB] OR adeno carcinoma\* [TIAB]) AND (drug therap\* [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB] OR CCRT [TIAB] OR combined modality therap\* [TIAB] OR chemoradiotherap\* [TIAB] OR chemo radiotherap\* [TIAB] OR chemoradiation\* [TIAB] OR radiochemotherap\* [TIAB])) AND (combined modality therap\* [TIAB] OR multidisciplinary treatment\* [TIAB] OR multimodal therap\* [TIAB] OR multimodal treatment\* [TIAB])) AND (locally advanced\* [TIAB] OR stage III\* [TIAB] OR stage IV\* [TIAB] OR stage I-III\* [TIAB] OR stage I-IV\* [TIAB] OR stage II/III\* [TIAB] OR stage II-III\* [TIAB] OR stage II-IV\* [TIAB] OR stage IIA-III\* [TIAB] OR stage IIB-III\* [TIAB] OR stage IIA-IV\* [TIAB] OR stage IIB-IV\* [TIAB] OR stage 3\* [TIAB] OR stage 4\* [TIAB] OR stage 1-3\* [TIAB] OR stage 1-4\* [TIAB] OR stage 2-3\* [TIAB] OR stage 2-4\* [TIAB] OR stage 2a-3\* [TIAB] OR stage 2a-4\* [TIAB] OR stages I-III\* [TIAB] OR stages I-IV\* [TIAB] OR stages II/III\* [TIAB] OR stages II-III\* [TIAB] OR stages II-IV\* [TIAB] OR stages IIB-III\* [TIAB] OR stages IIB-IV\* [TIAB] OR stages 1-3\* [TIAB] OR stages 1-4\* [TIAB] OR stages 2-3\* [TIAB] OR stages 2-4\* [TIAB] OR ("Neoplasm Staging" [MH] AND (III [TI] OR 3 [TI] OR IVA [TI] OR 4a [TI])))

[データベース] 医中誌 Web

[検索日] 2016年2月26日

((子宮頸部腫瘍;薬物療法/TH and 子宮頸部腫瘍;放射線療法/TH) or (子宮頸部腫瘍;薬物療法/TH and 放射線療法/TH) or (子宮頸部腫瘍;治療/TH and 放射線化学療法/TH) or (子宮頸部腫瘍;治療/TH and アジュバント放射線療法/TH) or ((子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (薬物療法/AL or 薬物治療/AL or 化学療法/AL) and (放射線療法/AL OR 放射線治療/AL)) or (子宮頸部腫瘍;薬物療法/TH and 子宮頸部腫瘍;外科的療法/TH) or (子宮頸部腫瘍;薬物療法/TH and 外科手術/TH) or (子宮頸部腫瘍;治療/TH and アジュバント化学療法/TH) or ((子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (薬物療法/AL or 薬物治療/AL or 化学療法/AL) and (手術/AL OR 外科/AL)) or ((子宮頸部腫瘍;薬物療法/TH and 腺癌/TH) or (子宮頸部腫瘍/TH and 腺癌;薬物療法/TH)) or ((子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (薬物療法/AL or 薬物治療/AL or 化学療法/AL) and (腺癌/AL or 腺がん/AL or 腺細胞癌/AL or 腺細胞がん/AL or 顆粒細胞癌/AL or 顆粒細胞がん/AL)) or (子宮頸部腫瘍;治療/TH and 集学的治療/TH) or ((子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL) and (集学的治療/AL or 集学的療法/AL))) and (局所進行/AL or IIIA/AL or IIIB/AL or III期/AL or IVA/AL or 3期/AL or 3a/AL or 3b/AL or 4a/AL or "stage III"/AL or "stage 3"/AL or "stage IVA"/AL or "stage 4a"/AL or "stage 1-3"/AL or "stage 2-3"/AL or ステージ III/AL or ステージ 3/AL or ステージ IVA/AL or ステージ 4a/AL or ステージ 1-3/AL or ステージ 2-3/AL or (腫瘍進行度/TH and (III/TI or 3a/TI or 3b/TI or 3-4/TI or IVA/TI or 4a/TI)))

## CQ22 Ⅲ・ⅣA期に対して初回手術療法は推奨されるか？

[データベース] PubMed

[検索日] 2016年2月2日

("Uterine Cervical Neoplasms/surgery" [MH] OR ((cervical [TI] OR cervix [TI]) AND (cancer [TI] OR neoplasm\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]) AND (surg\* [TIAB] OR operation\* [TIAB]) NOT medline [SB])) AND ((("Neoplasm Staging" [MH] OR stag\* [TIAB]) AND (advanced [TIAB] OR III\* [TIAB] OR IVA [TIAB] OR 4a [TIAB])) OR stage 3\* [TIAB])

[データベース] 医中誌 Web

[検索日] 2016年2月2日

((子宮頸部腫瘍/TH AND (SH= 外科的療法)) or ((子宮頸部腫瘍/AL OR 子宮頸癌/AL OR 子宮頸癌/AL OR 子宮頸がん/AL OR 子宮頸がん/AL) AND (手術/AL OR 外科/AL))) and (III期/AL OR 3期/AL OR IIIa期/AL OR 3a期/AL OR IIIb期/AL OR 3b期/AL OR IVA期/AL OR 4a期/AL OR ステージ III/AL

OR ステージ 3/AL OR ステージ IVA/AL OR ステージ 4a/AL)

### CQ23 IVB 期に対して推奨される治療は？

〔データベース〕 PubMed

〔検索日〕 2016 年 1 月 7 日

("Uterine Cervical Neoplasms/therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB])) AND (therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB] OR radiotherapy [TIAB] OR radiation [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB] OR surgery [TIAB] OR surgical [TIAB] OR operati\* [TIAB]) NOT medline [SB])) AND (IVB [TIAB] OR 4B [TIAB])

〔検索日〕 2016 年 2 月 26 日

("Uterine Cervical Neoplasms/drug therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR adenocarcinoma\* [TIAB] OR adeno carcinoma\* [TIAB]) NOT medline [SB])) AND (advanced\* [TIAB] OR "Neoplasm Recurrence, Local" [MH] OR recurrence\* [TIAB] OR recurrent\* [TIAB]) AND ("Molecular Targeted Therapy" [MH] OR molecular target\* [TIAB] OR targeted molecular\* [TIAB] OR "Bevacizumab" [MH] OR bevacizumab [TIAB])

〔データベース〕 医中誌 Web

〔検索日〕 2016 年 1 月 7 日

(子宮頸部腫瘍/TH OR 子宮頸部腫瘍/AL OR 子宮頸癌/AL OR 子宮頸癌/AL OR 子宮頸がん/AL OR 子宮頸がん/AL) and (VIB 期/AL OR 4B 期/AL) and ((SH= 治療の利用, 治療, 薬物療法, 外科の療法, 移植, 食事療法, 精神療法, 放射線療法) or 治療/TH or 治療/AL OR 療法/AL)

〔検索日〕 2016 年 2 月 26 日

(子宮頸部腫瘍;薬物療法/TH or (子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL or ((cervical/AL or cervix/AL) AND (cancer/AL or neoplasm\*/AL or adenocarcinoma\*/AL or adeno carcinoma\*/AL)))) and (進 行/AL or advanced/AL or 腫 瘍 再 発/TH or 再 発/AL or recurrence/AL or recurrent/AL) and (分子標的治療/TH or 分子標的/AL or "molecular target"/AL or "targeted molecular"/AL or Bevacizumab/TH or bevacizumab/AL or ベバシツマブ/AL or ベバシズマブ/AL or Avastin/AL or アバスチン/AL)

### CQ24 III・IV 期腺癌に対して推奨される治療は？

〔データベース〕 PubMed

〔検索日〕 2016 年 1 月 7 日

("Uterine Cervical Neoplasms/therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB])) AND (therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB] OR radiotherapy [TIAB] OR radiation [TIAB] OR chemotherap\* [TIAB] OR pharmacotherap\* [TIAB] OR surgery [TIAB] OR surgical [TIAB] OR operati\* [TIAB]) NOT medline [SB])) AND ("Adenocarcinoma" [MH] OR (adenocarcinoma\* [TIAB] NOT medline [SB])) AND (stage III\* [TIAB] OR stage 3\* [TIAB] OR III stage\* [TIAB] OR 3 stage\* [TIAB] OR stage IV\* [TIAB] OR stage 4\* [TIAB] OR IV stage\* [TIAB] OR 4 stage\* [TIAB])

〔データベース〕 医中誌 Web

〔検索日〕 2016 年 1 月 7 日

(子宮頸部腫瘍/TH OR 子宮頸部腫瘍/AL OR 子宮頸癌/AL OR 子宮頸癌/AL OR 子宮頸がん/AL OR 子宮頸がん/AL) and (腺 癌/TH OR 腺 癌/AL) and (III 期/AL OR 3 期/AL OR IV 期/AL OR 4 期/AL) and ((SH= 治療の利用, 治療, 薬物療法, 外科の療法, 移植, 食事療法, 精神療法, 放射線療法) or 治療/TH or 治療/AL OR 療法/AL)

**CQ25** TNM 分類の T3, T4 で傍大動脈リンパ節転移のある症例の治療は？

〔データベース〕 PubMed

〔検索日〕 2016 年 1 月 6 日

("Uterine Cervical Neoplasms/therapy" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]) AND (prevent\* [TIAB] OR radiotherapy [TIAB] OR radiation [TIAB] OR therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB]) NOT medline [SB])) AND (((para-aortic [TIAB] OR paraaortic [TIAB]) AND ("Lymphatic Irradiation" [MH] OR "Lymphatic Metastasis" [MH] OR "Lymphatic Diseases" [MH] OR "Lymph Nodes" [MH] OR lymph node\* [TIAB])) OR para aortic node\* [TIAB] OR paraaortic node\* [TIAB]))

〔データベース〕 医中誌 Web

〔検索日〕 2015 年 12 月 28 日

(子宮頸部腫瘍/TH OR 子宮頸部腫瘍/AL OR 子宮頸癌/AL OR 子宮頸癌/AL OR 子宮頸がん/AL OR 子宮頸がん/AL) and (大動脈/TH OR 傍大動脈/AL) and (リンパ行性転移/TH OR リンパ節郭清/TH OR リンパ系疾患/TH OR リンパ節/TH OR リンパ節/AL) and ((SH= 治療の利用, 治療, 薬物療法, 外科的療法, 移植, 食事療法, 精神療法, 放射線療法, リハビリテーション, 予防) or 治療/TH or 治療/AL OR 療法/AL) and (腫瘍進行度/TH or III/AL OR IV/AL)

**CQ26** 前治療として放射線治療が施行されていない場合、骨盤内に限局した再発に対して放射線治療は推奨されるか？

〔データベース〕 PubMed

〔検索日〕 2016 年 2 月 2 日

("Uterine Cervical Neoplasms" [MAJR] OR (gynecolog\* [TI] AND (cancer [TI] OR neoplasm\* [TI] OR carcinoma\* [TI] OR malignan\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI])) AND ("Neoplasm Recurrence, Local" [MH] OR "Neoplasm, Residual" [MH] OR recurren\* [TI] OR residual\* [TI] OR relapse\* [TI]) AND ("Pelvis" [MH] OR "Pelvic Neoplasms" [MH] OR "Vaginal Neoplasms" [MH] OR pelvis [TIAB] OR pelvic [TIAB]) OR ((cervical [TI] OR cervix [TI] OR gynecolog\* [TI] AND (cancer [TI] OR neoplasm\* [TI] OR carcinoma\* [TI] OR malignan\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]) NOT medline [SB]) AND (recurren\* [TIAB] OR residual\* [TIAB] OR relapse\* [TIAB]) AND (pelvis [TIAB] OR pelvic [TIAB] OR vaginal [TIAB])) AND ("Uterine Cervical Neoplasms/therapy" [MH] OR radiotherap\* [TIAB] OR ((radio [TIAB] OR radiat\* [TIAB]) AND therap\* [TIAB]) OR irradiat\* [TIAB] OR chemoradi\* [TIAB] OR radiochemo\* [TIAB] OR ((chemotherap\* [TIAB] OR (chemo [TIAB] AND therap\* [TIAB])) AND (radiotherap\* [TIAB] OR (radio [TIAB] AND therap\* [TIAB]) OR (radiat\* [TIAB] AND therap\* [TIAB])))

〔データベース〕 医中誌 Web

〔検索日〕 2016 年 2 月 5 日

(子宮頸部腫瘍/TH OR 子宮頸部腫瘍/TA OR 子宮頸癌/TA OR 子宮頸癌/TA OR 子宮頸がん/TA OR 子宮頸がん/TA OR 婦人科癌/TI OR 婦人科がん/TI OR 女性癌/TI OR 女性がん/TI) and (腫瘍転移/MTH or 腫瘍再発/MTH or 腫瘍残遺/MTH or 再発/TI) and (骨盤/TH or 骨盤/TA or 骨盤内腫瘍/TH or 腔腫瘍/TH or pelvic/TA or pelvis/TA) and ((子宮頸部腫瘍/TH and SH= 治療, 薬物療法, 外科的療法, 食事療法, 精神療法, 放射線療法) or 同時化学療法/TA or 放射線化学療法/TH or 薬物療法/TA or 薬物治療/TA or 化学療法/TA or 化学治療/TA or 腫瘍多剤併用療法/TH or 放射線療法/TH or 放射線療法/TA or 放射線治療/TA)

**CQ27 照射野内再発に対して推奨される治療は？**

〔データベース〕 PubMed

〔検索日〕 2016年1月27日

((("Uterine Cervical Neoplasms/surgery" [MAJR] OR ("Uterine Cervical Neoplasms" [MAJR] AND ("Pelvic Exenteration" [MH] OR pelvic exenteration\* [TIAB] OR "Hysterectomy" [MH] OR hysterectom\* [TIAB]))) AND ("Neoplasm Recurrence, Local" [MH] OR "Neoplasm, Residual" [MH] OR recurren\* [TI] OR residual [TI])) OR (((cervical [TI] OR cervix [TI] OR gynecolog\* [TI]) AND (cancer [TI] OR neoplasm\* [TI] OR carcinoma\* [TI] OR malignanc\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI])) NOT medline [SB]) AND (exenteration\* [TIAB] OR hysterectom\* [TIAB] OR surg\* [TI] OR resect\* [TI] OR dissect\* [TI] OR operation\* [TI]) AND (recurren\* [TIAB] OR residual [TIAB]))

〔データベース〕 医中誌 Web

〔検索日〕 2016年1月27日

(子宮頸部腫瘍/TH and SH= 治療, 薬物療法, 外科的療法, 食事療法, 精神療法, 放射線療法 or 子宮頸部腫瘍/TI or 子宮頸癌/TI or 子宮頸痛/TI or 子宮頸がん/TI or 子宮頸がん/TI or 婦人科癌/TI or 婦人科がん/TI or 女性癌/TI or 女性がん/TI) and (照射野内再発/TA or 腫瘍再発/MTH or 腫瘍-残遺/MTH or 再発/TI) and (骨盤内容除去術/TH or 子宮摘出術/TH or 手術/TI or 摘出/TI or 全摘/TI or 切除/TI or hysterectomy/TA or (pelvic/TA and exenteration/TA) or 放射線療法/TH or 放射線療法/TI or 放射線治療/TI)

**CQ28 照射野外再発, あるいは放射線治療を施行していない場合の骨盤外再発に対して推奨される治療は？**

〔データベース〕 PubMed

〔検索日〕 2016年2月3日, 2月10日

## 1. 傍大動脈リンパ節

("Uterine Cervical Neoplasms/therapy" [MH] OR (((cervical [TIAB] OR cervix [TIAB] OR gynecolog\* [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB] OR malignanc\* [TIAB] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI])) NOT medline [SB])) AND (para-aortic [TIAB] OR paraaortic [TIAB] OR para aortic node\* [TIAB] OR paraaortic node\* [TIAB]) AND ("Lymphatic Irradiation" [MH] OR "Lymphatic Metastasis" [MH] OR "Lymphatic Diseases" [MH] OR "Lymph Nodes" [MH] OR lymph node\* [TIAB]) AND (recurren\* [TIAB] OR relapse\* [TIAB]))

## 2. 脳転移

("Brain Neoplasms/secondary" [MH] AND ("Brain Neoplasms/surgery" [MAJR] OR "Brain Neoplasms/radiotherapy" [MAJR] OR "Brain Neoplasms/secondary" [MAJR])) AND (metasta\* [TI] OR oligometasta\* [TI]) AND (radiotherap\* [TI] OR radiosurgery [MH] OR radiosurg\* [TI] OR SRS [TI] OR WBRT [TI] OR irradiat\* [TI] OR ((radio [TI] OR radiation [TI]) AND therap\* [TI]) OR surg\* [TI] OR resect\* [TI] OR treatment\* [TI]) AND (brain [TI] AND (metasta\* [TI] OR oligometasta\* [TI]) NOT medline [SB])

## 3. 骨転移

("Bone Neoplasms/secondary" [MAJR] AND "Bone Neoplasms/therapy" [MAJR]) OR ((bone [TI] AND metasta\* [TI]) NOT medline [SB]) AND (metasta\* [TI] OR oligometasta\* [TI]) AND (radiotherap\* [TI] OR ((radio [TI] OR radiation [TI]) AND therap\* [TI])) OR irradiat\* [TI] OR "Radiotherapy" [MH] OR "Radioisotopes/therapeutic use" [MH])

## 4. 肺転移(手術)

("Lung Neoplasms/surgery" [MAJR] OR "Lung Neoplasms/secondary" [MAJR]) AND ((pulmonary [TI] OR lung [TI]) AND metasta\* [TI]) AND (metastasectom\* [TI] OR resect\* [TI] OR surg\* [TI]) OR (((pulmonary [TI] OR lung [TI]) AND metasta\* [TI]) NOT medline [SB]) AND (metastasectom\* [TI]

OR resect\* [TI] OR surg\* [TI]))

#### 4. 肺転移(放射線療法)

("Lung Neoplasms/radiotherapy" [MAJR] OR "Lung Neoplasms/secondary" [MAJR] OR Stereotactic body radiation therapy [TI] OR Stereotactic body radiotherapy [TI] OR SBRT [TI] OR ((pulmonary [TI] OR lung [TI]) AND (metasta\* [TI] OR oligometasta\* [TI])) OR Stereotactic body radiation therapy [TI] OR Stereotactic body radiotherapy [TI] OR SBRT [TI]) NOT medline [SB]) AND (((pulmonary [TI] OR lung [TI]) AND (metasta\* [TI] OR oligometasta\* [TI])) AND (radiotherap\* [TI] OR ((radio [TI] OR radiation [TI]) AND therap\* [TI])) OR irradiat\* [TI] OR Radiosurgery [MAJR])

[データベース] 医中誌 Web

[検索日] 2016年2月10日

#### 1. 傍大動脈リンパ節転移

(子宮頸部腫瘍/TH OR 子宮頸部腫瘍/TA OR 子宮頸癌/TA OR 子宮頸癌/TA OR 子宮頸がん/TA OR 子宮頸がん/TA OR 婦人科癌/TI OR 婦人科がん/TI OR 女性癌/TI OR 女性がん/TI) and (大動脈/TH OR 傍大動脈/TA) and (リンパ行性転移/TH OR リンパ節郭清/TH OR リンパ系疾患/TH OR リンパ節/TH OR リンパ節/TA) and (腫瘍転移/TH or 腫瘍再発/TH or 腫瘍-残遺/TH or 再発/TI or 転移/TI)

#### 2. 脳転移

(子宮頸部腫瘍/TH OR 子宮頸部腫瘍/TA OR 子宮頸癌/TA OR 子宮頸癌/TA OR 子宮頸がん/TA OR 子宮頸がん/TA OR 婦人科癌/TI OR 婦人科がん/TI OR 女性癌/TI OR 女性がん/TI) and ((脳腫瘍/TH and SH=転移性) or (脳/TA and 転移/TA) or (脳/TA and 再発/TA) or (brain/TA and metastasis/TA))

#### 3. 骨転移

(子宮頸部腫瘍/TH OR 子宮頸部腫瘍/TA OR 子宮頸癌/TA OR 子宮頸癌/TA OR 子宮頸がん/TA OR 子宮頸がん/TA OR 婦人科癌/TI OR 婦人科がん/TI OR 女性癌/TI OR 女性がん/TI) and ((骨腫瘍/TH and SH=転移性) or (骨/TI and 転移/TI) or (骨/TI and 再発/TI) or (bone/TI and metastasis/TI))

#### 4. 肺転移

(子宮頸部腫瘍/TH OR 子宮頸部腫瘍/TA OR 子宮頸癌/TA OR 子宮頸癌/TA OR 子宮頸がん/TA OR 子宮頸がん/TA OR 婦人科癌/TI OR 婦人科がん/TI OR 女性癌/TI OR 女性がん/TI) and ((肺腫瘍/TH and SH=転移性) or (肺/TI and 転移/TI) or (肺/TI and 再発/TI) or (lung/TI and metastasis/TI))

## CQ29 再発癌に対して全身化学療法を行う場合、推奨されるレジメンは？

[データベース] PubMed

[検索日] 2016年1月29日

("Uterine Cervical Neoplasms/drug therapy" [MAJR] AND ("Antineoplastic Combined Chemotherapy Protocols/therapeutic use" [MH] OR "Cisplatin" [MH] OR cisplatin [TIAB] OR "Bevacizumab" [MH] OR bevacizumab [TIAB] OR "Topotecan" [MH] OR topotecan [TIAB] OR "Cetuximab" [MH] OR cetuximab [TIAB] OR "Erlotinib Hydrochloride" [MH] OR erlotinib [TIAB] OR platinum resistant\* [TIAB] OR platinum sensitiv\* [TIAB])) OR (((cervical [TI] OR cervix [TI] OR gynecolog\* [TI]) AND (cancer [TI] OR neoplasm\* [TI] OR carcinoma\* [TI] OR malignanc\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]) NOT medline [SB]) AND (chemotherap\* [TI] OR drug therap\* [TI] OR drugtherap\* [TI] OR pharmacotherap\* [TI] OR cisplatin\* [TI] OR bevacizumab\* [TI] OR topotecan\* [TI] OR cetuximab\* [TI] OR erlotinib\* [TI] OR platinum resistan\* [TI] OR platinum sensitiv\* [TI]))

[データベース] 医中誌 Web

[検索日] 2016年1月29日

((子宮頸部腫瘍/TH) and (SH=薬物療法)) or (((子宮頸部腫瘍/TI or 子宮頸癌/TI or 子宮頸癌/TI or 子宮頸がん/TI or 子宮頸がん/TI or 婦人科癌/TI or 婦人科がん/TI or 女性癌/TI or 女性がん/TI) and (薬物/TA or 化学/TA) and (治療/TA or 療法/TA))) and (腫瘍多剤併用療法/TH or Cisplatin/TH or Cisplatin/TA or シスプラチン/TA or Bevacizumab/TH or Bevacizumab/TA or ベバシズマブ/TA or Topotecan/TH or Topotecan/TA or トポテカン/TA or Cetuximab/TH or Cetuximab/TA or セツキシマ



ブ/TA or Erlotinib/TH or Erlotinib/TA or エルロチニブ/TA) and (腫瘍転移/MTH or 腫瘍再発/MTH or 腫瘍-残遺/MTH or 再発/TI or 転移/TI)

### CQ30 妊娠中の CIN 3・AIS に対して推奨される対応は？

[データベース] PubMed

[検索日] 2016年2月13日

("Cervical Intraepithelial Neoplasia" [MH] OR "Cervical Intraepithelial Neoplasia" [TIAB] OR "high grade squamous intraepithelial lesion" [TIAB] OR "high grade squamous intraepithelial lesions" [TIAB] OR "high grade squamous intraepithelial neoplasia" [TIAB] OR "Squamous Intraepithelial Lesions" [TW] AND "High grade" [TIAB]) OR HSIL [TIAB] OR "preinvasive adenocarcinoma" [TIAB] OR "intraepithelial adenocarcinoma" [TIAB] OR "intraepithelial adenocarcinomas" [TIAB] OR "Adenocarcinoma in situ" [TW] OR "pre malignant lesion" [TIAB] OR "pre malignant lesions" [TIAB] OR "precancerous lesion" [TIAB] OR "precancerous lesions" [TIAB] OR AIS [TIAB]) AND (cervical [TIAB] OR cervix [TIAB]) AND (("associated with" [TIAB] AND pregnancy [TIAB]) OR "in pregnancy" [TIAB] OR "during pregnancy" [TIAB] OR "complicating pregnancy" [TIAB] OR gestation [TIAB] OR "Pregnancy Trimesters" [MH] OR "Pregnant Women" [MH] OR "Pregnancy Complications, Neoplastic" [MH])

[データベース] 医中誌 Web

[検索日] 2016年2月7日

((@ 子宮頸部腫瘍/TH and @ 上皮内癌/TH) or 子宮頸部上皮内腫瘍/TH or (@ 上皮内腺癌/TH and @ 子宮頸部腫瘍/TH) or (((@ 子宮頸部腫瘍/TH and @ 腺扁平上皮癌/TH) or (@ 子宮頸部腫瘍/TH and @ 扁平上皮癌/TH)) and (高度/AL or 高悪性/AL)) or CIN3/AL or "CIN 3"/AL or ((AIS/AL or HSIL/AL) and (子宮/AL)) and (妊娠期/TH or 妊娠合併症-腫瘍性/TH or 妊娠中/AL or 妊婦/AL) and (治療/TH or 治療/AL or 療法/AL or 妊娠管理/TH or 妊娠管理/AL)

### CQ31 妊娠中に IA 期が疑われる場合の対応は？

[データベース] PubMed

[検索日] 2016年2月13日

("Adenocarcinoma" [MH] OR "Carcinoma, Squamous Cell" [MH] OR "squamous cell carcinoma" [TIAB] OR "squamous cell carcinomas" [TIAB] OR adenocarcinoma [TIAB] OR adenocarcinomas [TIAB] OR "Uterine Cervical Neoplasms" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]))) AND (("associated with" [TIAB] AND pregnancy [TIAB]) OR "in pregnancy" [TIAB] OR "during pregnancy" [TIAB] OR "complicating pregnancy" [TIAB] OR gestation [TIAB] OR pregnancy trimester [MH] OR Pregnant Women [MH] OR "Pregnancy Complications, Neoplastic" [MH]) AND (Therapy [MeSH Subheading] OR radiotherapy [TIAB] OR radiation [TIAB] OR therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB])

[データベース] 医中誌 Web

[検索日] 2016年2月7日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL or (@ 子宮頸部腫瘍/TH and @ 腺癌/TH) or 子宮頸部腺がん/AL or 子宮頸部腺癌/AL or 子宮頸部腺がん/AL or 子宮頸部腺癌/AL) and (妊娠期/TH or 妊娠合併症-腫瘍性/TH or 妊娠中/AL or 妊婦/AL) and (治療/TH or 治療/AL or 療法/AL or 妊娠管理/TH or 妊娠管理/AL)

**CQ32 妊娠中のI B・II期に対して推奨される治療は？**

〔データベース〕 PubMed

〔検索日〕 2016年2月13日

("Adenocarcinoma" [MH] OR "Carcinoma, Squamous Cell" [MH] OR "squamous cell carcinoma" [TIAB] OR "squamous cell carcinomas" [TIAB] OR adenocarcinoma [TIAB] OR adenocarcinomas [TIAB] OR "Uterine Cervical Neoplasms" [MH] OR ((cervical [TIAB] OR cervix [TIAB]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB]))) AND (("associated with" [TIAB] AND pregnancy [TIAB]) OR "in pregnancy" [TIAB] OR "during pregnancy" [TIAB] OR "complicating pregnancy" [TIAB] OR gestation [TIAB] OR "Pregnancy Trimesters" [MH] OR "Pregnant Women" [MH] OR "Pregnancy Complications, Neoplastic" [MH]) AND (Therapy [MeSH Subheading] OR radiotherapy [TIAB] OR radiation [TIAB] OR therapy [TIAB] OR therapeutic\* [TIAB] OR treatment [TIAB])

〔データベース〕 医中誌 Web

〔検索日〕 2016年2月7日

(子宮頸部腫瘍/TH or 子宮頸部腫瘍/AL or 子宮頸癌/AL or 子宮頸癌/AL or 子宮頸がん/AL or 子宮頸がん/AL or (@子宮頸部腫瘍/TH and @腺癌/TH) or 子宮頸部腺がん/AL or 子宮頸部腺癌/AL or 子宮頸部腺がん/AL or 子宮頸部腺癌/AL) and (妊娠期/TH or 妊娠合併症-腫瘍性/TH or 妊娠中/AL or 妊婦/AL) and (治療/TH or 治療/AL or 療法/AL or 妊娠管理/TH or 妊娠管理/AL)

**CQ33 治療後の経過観察として推奨される間隔は？**

〔データベース〕 PubMed

〔検索日〕 2016年1月16日

((("Uterine Cervical Neoplasms/therapy" [MH] AND (prognos\* [TIAB] OR after treatment [TIAB] OR "Neoplasm Recurrence, Local" [MH] OR postoperative [TIAB] OR post operative [TIAB] OR posttreatment [TIAB] OR post treatment [TIAB] OR surviv\* [TIAB])) OR (((cervical [TI] OR cervix [TI]) AND (cancer [TI] OR neoplasm\* [TI] OR carcinoma\* [TI])) NOT medline [SB]) AND (prognos\* [TIAB] OR after treatment [TIAB] OR recurren\* [TIAB] OR postoperative [TIAB] OR post operative [TIAB] OR posttreatment [TIAB] OR post treatment [TIAB] OR surviv\* [TIAB]))) AND (follow up [TIAB] OR followup [TIAB] OR "Follow-Up Studies" [MH] OR QOL [TI] OR quality of life [TI] OR surveillance [TI] OR management [TI] OR program\* [TI] OR screening [TI] OR protocol\* [TI] OR procedure\* [TI] OR assessment [TI] OR guideline\* [TI]) AND ("Time Factors" [MH] OR interval [TIAB] OR intervals [TIAB] OR period\* [TIAB] OR term [TIAB])

〔データベース〕 医中誌 Web

〔検索日〕 2016年1月16日

((子宮頸部腫瘍/TH OR 子宮頸部腫瘍/TA OR 子宮頸癌/TA OR 子宮頸癌/TA OR 子宮頸がん/TA OR 子宮頸がん/TA) and (経過観察/TA OR フォローアップ/TA OR followup/TA OR "follow up"/TA OR 生活の質/TH OR QOL/TA OR "quality of life"/TA OR 健康管理/TH OR 婦人科検査/TH) and (術後期/TH OR 術後/TA OR 治療後/TA OR 予後/MH OR 予後/TA OR 腫瘍再発/TH) and (間隔/TA OR 期間/TA OR 時間因子/TH) or ((生殖器腫瘍-女性/MTH OR 子宮頸癌/TA OR 子宮頸癌/TA OR 子宮頸がん/TA OR 子宮頸がん/TA OR 婦人科癌/TA OR 婦人科がん/TA OR 女性癌/TA OR 女性がん/TA) and (経過観察/TI OR フォローアップ/TI OR followup/TI OR "follow up"/TI OR 生活の質/MTH OR QOL/TI OR "quality of life"/TI OR 健康管理/MTH) and (術後期/MTH OR 術後/TI OR 治療後/TI OR 予後/TI OR 腫瘍再発/MTH OR 生存/TI))

**CQ34 治療後の経過観察において留意すべき項目は？**

〔データベース〕 PubMed

[検索日] 2016年1月14日, 1月16日

("Uterine Cervical Neoplasms" [MAJR] OR (gynecolog\* [TI] AND (cancer [TI] OR neoplasm\* [TI] OR carcinoma\* [TI] OR malignan\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI]))) AND (prognos\* [TIAB] OR after treatment\* [TIAB] OR Neoplasm Recurrence, Local [MH] OR postoperative [TIAB] OR post operative [TIAB] OR posttreatment\* [TIAB] OR post treatment\* [TIAB] OR surviv\* [TIAB]) AND (Gynecological Examination [MH] OR Gynecological Exam\* [TIAB] OR Pelvic Exam\* [TIAB] OR Vaginal Exam\* [TIAB] OR "Cytodiagnosis" [MH] OR "Biomarkers, Tumor" [MH] OR "Mass Chest X-Ray" [MH] OR "Magnetic Resonance Imaging" [MH] OR "Tomography, X-Ray Computed" [MH] OR "Positron-Emission Tomography" [MH] OR imaging test\* [TIAB])) OR (((cervical [TIAB] OR cervix [TIAB] OR gynecolog\* [TI]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB] OR malignan\* [TI] OR adenocarcinoma\* [TI] OR adeno carcinoma\* [TI])) NOT medline [SB]) AND (pelvic exam\* [TIAB] OR cytology [TIAB] OR tumor marker\* [TIAB] OR Chest X-ray [TIAB] OR MRI [TIAB] OR CT [TIAB] OR PET [TIAB] OR imaging test\* [TIAB]) AND (prognos\* [TIAB] OR after treatment\* [TIAB] OR recurren\* [TIAB] OR postoperative [TIAB] OR post operative [TIAB] OR posttreatment\* [TIAB] OR post treatment\* [TIAB] OR surviv\* [TIAB])) AND (follow up [TIAB] OR followup [TIAB] OR follow up studies [MH] OR QOL [TI] OR quality of life [TI] OR surveillance [TI] OR management [TI] OR program\* [TI] OR screening [TI] OR protocol\* [TI] OR procedure\* [TI] OR assessment [TI] OR guideline\* [TI])

[データベース] 医中誌 Web

[検索日] 2016年1月16日

((子宮頸部腫瘍/TH OR 子宮頸部腫瘍/TA OR 子宮頸癌/TA OR 子宮頸癌/TA OR 子宮頸がん/TA OR 子宮頸がん/TA OR 婦人科癌/TI OR 婦人科がん/TI OR 女性癌/TI OR 女性がん/TI) and (フォローアップ/TA OR followup/TA OR "follow up"/TA OR 追跡研究/TH OR 生活の質/TH OR QOL/TI OR "quality of life"/TI OR 健康管理/TH OR 管理/TI OR 観察/TI) and (術後期/TH OR 術後/TA OR 治療後/TA OR 予後/MTH OR 予後/TI OR 腫瘍再発/TH OR 再発/TI) and (婦人科検査/TH OR 細胞診/TH OR 胸部X線集団検診/TH OR 画像診断/TH OR X線CT/TH OR 陽電子放射型断層撮影/TH OR 画像検査/TA OR 内診/TA OR MRI/TI OR CT/TI OR PET/TI)) or ((子宮頸部腫瘍/TH OR 子宮頸部腫瘍/TA OR 子宮頸癌/TA OR 子宮頸癌/TA OR 子宮頸がん/TA OR 子宮頸がん/TA OR 婦人科癌/TI OR 婦人科がん/TI OR 女性癌/TI OR 女性がん/TI) and (術後期/TH OR 術後/TA OR 治療後/TA OR 予後/MTH OR 予後/TI OR 腫瘍再発/TH OR 再発/TI) and (健康管理/TH OR 健康管理/TA OR 更年期障害/TH OR メンタルヘルス/TA OR 精神保健/TH OR ヘルスケア/TA OR 閉経/TH OR 閉経/TI OR 骨粗鬆症/TH OR 骨粗鬆症/TI OR 脂質異常症/TH OR 脂質/TI OR 経過観察/TI OR フォローアップ/TI OR followup/TI OR "follow up"/TI OR 生活の質/TH OR QOL/TI OR "quality of life"/TI))

### CQ35 治療後のホルモン補充療法は推奨されるか？

[データベース] PubMed

[検索日] 2016年1月19日

("Uterine Cervical Neoplasms" [MH] OR ((cervical [TIAB] OR cervix [TIAB] OR gynecolog\* [TI]) AND (cancer [TIAB] OR neoplasm\* [TIAB] OR carcinoma\* [TIAB] OR malignan\* [TI] OR adenocarcinoma\* [TIAB] OR adeno carcinoma\* [TIAB]) NOT medline [SB])) AND (prognos\* [TIAB] OR "Neoplasm Recurrence, Local" [MH] OR recurren\* [TIAB] OR after treatment [TIAB] OR postoperative [TIAB] OR post operative [TIAB] OR posttreatment [TIAB] OR post treatment [TIAB] OR surviv\* [TIAB]) AND ("Hormone Replacement Therapy" [MH] OR (therap\* [TIAB] AND hormone [TIAB]) OR HRT [TIAB] OR MHT [TIAB])

[データベース] 医中誌 Web

[検索日] 2016年1月18日

(子宮頸部腫瘍/TH OR 子宮頸部腫瘍/TA OR 子宮頸癌/TA OR 子宮頸癌/TA OR 子宮頸がん/TA OR 子宮

頸がん/TA OR 婦人科癌/TI OR 婦人科がん/TI OR 女性癌/TI OR 女性がん/TI) and (術後期/TH OR 術後/TA OR 治療後/TA OR 予後/TH OR 予後/TA OR 腫瘍再発/TH) and (ホルモン補充療法/TH OR (ホルモン/TA AND (療法/TA OR 治療/TA)) OR HRT/TA OR MHT/TA)